Semax Research Profile: ACTH Analog Nootropic Peptide for Cognitive Enhancement and Neuroprotection Research (2026)

> Research Use Only: This content is for research and educational purposes only. Semax is a research peptide not approved by the FDA for human use in the United States or EU. Information on this page is intended for qualified researchers and should not be construed as medical advice, diagnosis, or treatment recommendations.

What Is Semax?

Semax is a synthetic heptapeptide analog of the N-terminal fragment of adrenocorticotropic hormone (ACTH), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Unlike full-length ACTH (39 amino acids) or the 4-10 fragment it derives from, Semax does not significantly activate adrenal cortisol production — enabling its use as a selective neuroprotective and cognitive-enhancing research compound without the glucocorticoid effects of ACTH.

For dosing, reconstitution, and protocol details, see our Semax Dosage Protocol Guide: Intranasal Research Protocols, Reconstitution & BDNF Mechanisms (2026).

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved in Russia and Ukraine for use in treating stroke, transient ischemic attack (TIA), and cognitive dysfunction. This approval status makes Semax the most clinically advanced nootropic peptide with documented human use, distinguishing it from purely preclinical research compounds in the same category.

The primary pharmacological signature of Semax is its ability to upregulate BDNF (brain-derived neurotrophic factor) expression and its receptor TrkB in the hippocampus and cortex. This neurotrophic mechanism, combined with neuroprotective and anti-inflammatory actions, has established Semax as a leading research tool for studying cognitive function, neuroprotection, and BDNF biology.

Mechanism of Action

ACTH Receptor Interaction

Semax retains the core ACTH(4-7) sequence (Met-Glu-His-Phe) responsible for melanocortin receptor binding, along with Pro-Gly-Pro modifications that enhance metabolic stability. Its primary interactions include:

Melanocortin receptor subtypes:

• •MC4R (melanocortin 4 receptor): Expressed in hypothalamus and various brain regions; mediates many CNS effects
• •MC3R: Expressed in limbic regions; role in feeding behavior and neuroprotection
• •Low affinity for MC2R (ACTH receptor driving cortisol production): Explains the absence of significant adrenal effects

Receptor-independent mechanisms:

Research indicates Semax activates multiple pathways that may not be fully explained by melanocortin receptor binding alone, including direct BDNF regulation and modulation of serotonin metabolism.

BDNF Upregulation

The most extensively documented mechanism of Semax is upregulation of BDNF and the BDNF receptor TrkB:

Direct BDNF gene regulation:

• •Semax increases BDNF mRNA expression in hippocampus within hours of administration
• •Protein levels of mature BDNF rise within 24-48 hours
• •The effect is most pronounced in the CA1, CA3, and dentate gyrus of the hippocampus
• •Frontal cortex and striatum also show BDNF upregulation

TrkB receptor upregulation:

• •Semax increases TrkB expression in parallel with BDNF
• •Increased receptor density amplifies the effect of available BDNF
• •TrkB-PI3K-Akt signaling provides neuroprotective and pro-survival effects
• •TrkB-MAPK-ERK signaling supports synaptic plasticity and memory consolidation

BDNF-mediated downstream effects:

• •Long-term potentiation (LTP) enhancement
• •Dendritic spine density increases
• •Increased AMPA receptor trafficking to synapses
• •Improved spatial memory and cognitive flexibility

Neuroprotective Mechanisms

Beyond BDNF, Semax exerts multiple neuroprotective effects:

Oxidative stress reduction:

• •Decreased lipid peroxidation in ischemic brain tissue
• •Upregulation of catalase and superoxide dismutase (antioxidant enzymes)
• •Reduced reactive oxygen species (ROS) production following excitotoxic challenge

Excitotoxicity protection:

• •Reduced NMDA receptor-mediated calcium influx
• •Protection against glutamate-induced neuronal death in vitro
• •Preservation of mitochondrial membrane potential during metabolic challenge

Anti-inflammatory effects:

• •Reduced pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) in neural tissue
• •Modulation of microglia activation toward anti-inflammatory (M2) phenotype
• •Decreased NF-kB signaling in neuronal and glial cells

Cerebral blood flow enhancement:

• •Promotes vasodilation in cerebral vasculature
• •May reduce ischemia-reperfusion injury severity
• •Enhanced cerebral perfusion in preclinical stroke models

Serotonin System Modulation

Semax has documented effects on the serotonergic system:

• •Increased serotonin release in the hippocampus
• •Enhanced serotonin uptake regulation
• •5-HT2A and 5-HT3 receptor activity modulation
• •These serotonergic effects contribute to mood-enhancing and anxiolytic properties observed in animal models

Enkephalin System Effects

The Gly-Pro C-terminal sequence in Semax is structurally similar to endogenous enkephalin-degrading peptides, and research has documented:

• •Inhibition of enkephalin-degrading enzymes
• •Increased endogenous enkephalin availability in specific brain regions
• •Opioid system modulation contributing to analgesic and mood effects

Published Research

Neuroprotection and Stroke Research

Russian Clinical Data

Semax has the most extensive human clinical database of any nootropic peptide:

• •Approved in Russia for acute ischemic stroke treatment
• •Clinical studies demonstrate significant reduction in post-stroke functional deficits
• •Intranasal Semax (0.1% solution, 300 mcg/day) accelerates neurological recovery vs. standard care
• •NIHSS (stroke severity) scores improve more rapidly in Semax-treated patients

Mechanism in Ischemia

In rodent middle cerebral artery occlusion (MCAO) models:

• •Infarct volume reduced by 25-40% in Semax-treated vs. saline controls
• •Neurological deficit scores significantly better at 24h and 7-day assessments
• •BDNF levels in peri-infarct tissue are significantly higher in treated animals
• •Preservation of hippocampal neurons correlates with cognitive outcome improvements

A clinical efficacy study of intranasal Semax in patients at different stages of ischemic stroke found measurable benefit on neurological outcomes when administered during the acute treatment window, consistent with the BDNF/NGF induction mechanism described above (Skvortsova et al., 2018, Zh Nevrol Psikhiatr Im S S Korsakova).

TIA (Transient Ischemic Attack) Prevention

Research in high-risk TIA patients:

• •Semax reduces frequency of TIA recurrence
• •Cognitive deficits following TIA are attenuated
• •Vascular endothelial function markers improve

Cognitive Enhancement Research

Attention and Learning

Multiple rodent studies document Semax's cognitive effects:

• •Improved acquisition of conditioned reflexes (classical and operant)
• •Enhanced working memory in radial arm maze
• •Faster reversal learning (cognitive flexibility)
• •Improved attention set-shifting (analogous to human executive function)

Chronic Stress and Depression Models

Semax demonstrates antidepressant and anxiolytic effects:

• •Forced swim test: Reduced immobility (indicating antidepressant-like effect)
• •Elevated plus maze: Increased open arm exploration (reduced anxiety)
• •Chronic unpredictable stress models: Protection against stress-induced BDNF reduction
• •The serotonergic and BDNF mechanisms likely underlie these effects

Human Cognitive Studies

Limited controlled studies in humans demonstrate:

• •Improved attention and short-term memory in healthy volunteers (single intranasal doses)
• •Enhanced EEG alpha wave activity (associated with focused attention)
• •Improved performance on digit span and reaction time tests

Attention Deficit Research

Given the overlap between Semax's mechanism and treatments for ADHD:

• •Animal models of impaired attention (5-choice serial reaction time task) show improvement with Semax
• •Dopaminergic and serotonergic modulation by Semax affects prefrontal cortex attention circuits
• •This makes Semax a research tool for studying attention regulation mechanisms

Anxiety and Mood Research

Animal Model Data:

• •Semax reduces anxiety-like behavior in multiple models (elevated plus maze, open field, light-dark box)
• •Antidepressant effects in forced swim and tail suspension tests
• •These effects appear distinct from sedation (motor activity is preserved or enhanced)

Possible Mechanisms:

• •BDNF upregulation (BDNF is reduced in depression)
• •Serotonin system modulation
• •HPA axis normalization through ACTH-like effects without cortisol elevation

Research Specifications

• •Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (heptapeptide)
• •Molecular weight: 813.9 Da
• •Formula: C37H51N9O10S
• •CAS Number: 80714-61-0
• •Primary receptor targets: MC3R, MC4R (melanocortin receptors)
• •Key downstream target: BDNF/TrkB signaling axis
• •Plasma half-life: ~5-10 minutes (IV); longer for intranasal (via olfactory pathways)
• •CNS penetration: Yes (intranasal route via olfactory nerve); poor systemic (subcutaneous)
• •Available forms: Lyophilized powder; also available as nasal spray solution (0.1%)
• •Reconstitution: Sterile water or saline
• •Primary administration route: Intranasal (preferred for CNS research)
• •Storage (lyophilized): -20°C
• •Storage (solution): 4°C; use within 30 days
• •Target purity: >=98% by HPLC
• •Classification: Approved drug in Russia/Ukraine; RUO in US/EU

Practical Research Considerations

Administration Routes and CNS Delivery

Semax's route of administration critically affects its pharmacological profile:

Intranasal (preferred for CNS effects):

• •Bypasses the blood-brain barrier via olfactory nerve pathways
• •Peptide enters CNS directly through the nasal mucosa-olfactory bulb connection
• •Volume: 100-300 mcg per administration (typically in 0.1-0.2% solution)
• •Fast onset: CNS effects within 10-30 minutes
• •Clinical formulations use 0.1% concentration (1 mg/mL)

Subcutaneous injection:

• •Lower CNS exposure compared to intranasal (poor BBB penetration of peptide)
• •Used in some animal studies at higher doses to compensate
• •More appropriate for peripheral/systemic effects research

Intravenous (research use):

• •Excellent bioavailability but very short half-life (~5-10 min)
• •Requires continuous infusion for sustained effects
• •Used in acute mechanistic studies

Reconstitution Protocol

1. Allow vial to reach room temperature

2. Add sterile water or saline to desired concentration

3. For intranasal use: target 0.1% (1 mg/mL) concentration

4. Gently swirl to dissolve; avoid vigorous agitation

5. Refrigerate at 4°C; use within 30 days

6. For animal intranasal administration: microinjection with calibrated pipette or commercial nose adaptor

Dosing Reference

Clinical doses (from Russian approval):

• •Intranasal: 300-600 mcg/day (3 drops of 0.1% solution per nostril)
• •Treatment courses: 5-14 days for acute conditions
• •Cognitive enhancement protocols: 5-10 day courses

Animal research doses:

• •Subcutaneous: 50-100 mcg/kg
• •Intranasal: 25-50 mcg/kg (lower dose sufficient due to direct CNS delivery)
• •Typical frequency: Once or twice daily for 7-14 days

Semax-SELANK combination: Russian research has explored combining Semax with Selank (an anxiolytic peptide) for complementary effects — a research strategy that may inform mechanistic studies.

Safety Profile and Interactions

Clinical Safety Data

Based on Russian approval and clinical experience:

Common adverse effects:

• •Local nasal irritation (with intranasal administration): 5-10% of patients
• •Mild headache: Occasional
• •Dizziness: Rare
• •No sedation or cognitive impairment at therapeutic doses

Systemic safety:

• •No significant changes in blood pressure or heart rate
• •No hepatic or renal function changes in clinical studies
• •No significant effect on cortisol levels (key safety advantage over ACTH)
• •No immunosuppressive effects observed

Long-term safety:

• •Russian clinical experience spans 25+ years without major safety signals
• •No addiction or dependence potential documented
• •No tolerance to cognitive effects reported in clinical use

Preclinical Safety Data

• •No genotoxicity in Ames test or chromosomal aberration assays
• •No significant organ toxicity in rodent studies at 10-100x therapeutic doses
• •No teratogenic effects in standard reproductive toxicity studies
• •Favorable therapeutic index based on available data

Drug Interactions

Potential interactions to consider:

• •Antidepressants (SSRIs, SNRIs): Additive serotonergic effects (pharmacodynamic)
• •BDNF-related compounds (P21, dihexa): Potentially additive neurotrophic effects
• •Cognitive enhancers (noopept, piracetam): Mechanistically complementary
• •Anxiolytics: Additive CNS depressant effects possible with benzodiazepines
• •MAO inhibitors: Caution due to serotonergic component

Comparison to Related Compounds

Semax vs. Selank

Selank is a related Russian neuropeptide with complementary but distinct effects:

Combined Semax + Selank protocols are used in Russian clinical practice for balanced nootropic and anxiolytic effects.

Semax vs. P21

Both promote BDNF upregulation but through different mechanisms:

Semax vs. Dihexa

Different cognitive enhancement mechanisms:

Semax vs. Selank

Both are synthetic ACTH-fragment analogs with nootropic research applications but differ in primary emphasis:

• •Selank acts primarily through anxiolytic and immunomodulatory mechanisms
• •Semax acts centrally through BDNF upregulation and serotonergic neuroprotective pathways
• •Selank is more relevant for anxiety, immune modulation, and stress-response research
• •Semax is more relevant for CNS-specific cognitive enhancement and neuroprotective research
• •Both compounds have substantial Russian clinical research and favorable preclinical safety profiles

Semax in Specific Research Contexts

Post-Stroke Neuroregeneration

The approved clinical indication drives active research questions:

• •Optimal timing of Semax administration relative to ischemia onset
• •Duration of treatment course for maximum benefit
• •Biomarkers predicting response (baseline BDNF, stroke volume)
• •Combination with thrombolytics (tPA) for additive neuroprotection
• •Prevention of post-stroke depression (BDNF mechanism)

Traumatic Brain Injury Research

TBI shares some neuropathological features with stroke:

• •Semax reduces secondary injury cascade in rodent TBI models
• •Cognitive recovery is accelerated compared to untreated TBI controls
• •BDNF induction is the primary proposed mechanism
• •Practical advantage: intranasal administration is feasible even in acute TBI

Neurodegenerative Disease Prevention

The neuroprotective profile of Semax positions it for disease-prevention research:

• •Alzheimer's disease: BDNF deficiency is well-documented; Semax could address this
• •Parkinson's disease: Serotonergic effects and possible dopaminergic protection
• •Multiple sclerosis: Anti-inflammatory effects in neural tissue are relevant
• •Amyotrophic lateral sclerosis (ALS): BDNF is neuroprotective for motor neurons

Performance and Resilience Research

Beyond disease, Semax is studied for optimizing healthy brain function:

• •Performance under stress: Preservation of cognitive function during acute stress exposure
• •Sleep deprivation compensation: Some evidence of maintained performance with Semax
• •High-altitude cognitive decline: BDNF and cerebrovascular effects relevant for hypoxia research
• •Cognitive aging: Prevention of BDNF decline and cognitive attrition in healthy aging models

Internal Research Tools

For researchers working with Semax, Peptides.SO provides:

• •Semax Peptide Page: Browse verified research suppliers, pricing, and availability
• •Compare Semax Suppliers: Compare 24+ verified suppliers by price, purity, and credentials
• •Peptide Calculator: Calculate precise intranasal dosing volumes and concentration parameters
• •Stack Builder: Design multi-peptide cognitive research protocols

Related compounds for neuroprotection and cognitive research:

• •P21 - CNTF-derived peptide for neurogenesis and BDNF research
• •Dihexa - HGF/MET agonist for synaptogenesis research
• •Selank - related ACTH-fragment analog with anxiolytic and cognitive research applications

Important Research Disclaimer

While Semax is approved as a pharmaceutical in Russia and Ukraine for specific neurological indications, it is classified as a research-use-only compound in most Western countries including the United States and EU member states. This article is intended for scientific educational purposes only and does not constitute medical advice. Semax should be studied within appropriate regulatory frameworks and with ethical oversight. Researchers in jurisdictions where Semax lacks regulatory approval should consult applicable regulations before initiating studies.

For research purposes only. Clinical use outside of approved jurisdictions and indications requires appropriate regulatory authorization.

---

Key Scientific References

1. Kolomin T, et al. (2013) A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Neuroscience & Medicine, 4, 223-252. Full Text

2. Sebentsova EA, et al. (2018) Long-Term Changes in Behavior and the Content of BDNF in the Rat Brain Caused by Neonatal Isolation: The Effects of an Analog of ACTH(4-10) Semax. Neurochemical Journal, 12(1), 53-63. ResearchGate

3. Manchenko DM, et al. (2012) The Protective Effect of Semax in a Model of Stress-Induced Impairment of Memory and Behavior in White Rats. Biology Bulletin, 45(4), 344-353. Springer

4. Skvortsova VI, et al. (2018) The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. PubMed

5. Shadrina MI, et al. (2010) Comparison of Temporary Dynamics of NGF and BDNF Gene Expression in Rat Hippocampus, Frontal Cortex, and Retina Under Semax Action. J Mol Neurosci, 41(1), 30-35. PubMed

Further Reading:

• •Methylene Blue: Mitochondrial Enhancer for Neuroprotection Research
• •Dihexa: HGF Receptor Agonist for Cognitive and Synaptogenic Research
• •P21 (P021): CNTF-Derived Peptide for Neurogenesis and Memory Research
• •Irisin (FNDC5): Complete Research Profile — The Exercise-Induced Myokine in Metabolic, Neuroprotection, and Bone Biology Research (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder